Tecfidera (BG-12) Nrf2 Activator Approved by FDA for Multiple Sclerosis (MS) Treatment
Although there is no treatment that will cure Multiple Sclerosis, there are three oral medications approved by the FDA to be a first-line treatment to slow down the progression of the disease.
Biogen

Although there is no treatment that will cure Multiple Sclerosis, there are three oral medications approved by the FDA to be a first-line treatment to slow down the progression of the disease.

Dimethyl Fumarate (Tecfidera, Biogen Idec)  joins fingolimod (Gilenya) and teriflunomide (Aubagio) as the new “kid on the block”. It is specifically approved for adults with relapsing-remitting Multiple Sclerosis.

Dimethyl fumarate is a drug that activates the nuclear factor-like2 (Nrf2) pathway. The study of NRF2 is a relatively new approach to lowering oxidative stress which is associated with hundreds of disease states (not just MS).

Tecfidera lowered MS relapses and lesions on the brain as well as worsening of the disability compared to the placebo group.

Dimethyl fumarate reduced the percentage of patients who experienced relapses 44% to 53% as measured by the Expanded Disability Status Scale (EDSS)

Biogen Idec MA, Cambridge, Mass., has been assigned a patent (8,399,514)  for the "treatment for multiple sclerosis."

The following abstract from the patent document states: "Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain methods of utilizing such compounds in therapy for neurological disease, particularly, for slowing or reducing demyelination, axonal loss, or neuronal and oligodendrocyte death."

The patent application was filed on Feb. 13, 2012 (13/372,426). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=8,399,514&OS=8,399,514&RS=8,399,514

 

Sign Up for Our Newsletter



Read More

Oxidative Stress
New Protandim Study – International Formula Impact on Oxidative Stress
There are numerous studies about the USA Protandim formula. This one is about the International formulation.
Augusta Nrf2 Study
Augusta University Discovers How Nrf2 Activator Preserves Sight in Retinal Degeneration Model
“We are very, very pleased that we can now explore the mechanisms,”, mentioned Dr. Sylvia Smith, chair of the Department of Cellular Biology and Anatomy at the Medical College of Georgia at Augusta University and co-director of the James and Jean Culver Vision Discovery Institute at AU.
persistent fibrosis
Reversal of persistent fibrosis in aging by targeting nox4-Nrf2 redox imbalance – Sciencemag.org
This is a promising study because the current treatments of pathological and cystic fibrosis are costly and very time consuming. Persistent fibrosis in lungs of aged mice was caused by the loss of cellular redox balance. The mice in the study with low NRF2 expression had a higher incidence of progressive lung disease. Tissues from human lung samples demonstrated this same Nox4-Nrf2 imbalance.

Next Steps

Get Our Free Newsletter

View Resources

Take Our Quiz

0

PROJECTS COMPLETED

0

ACTIVE CLIENTS

0

CUPS OF COFFEE

0

HAPPY CLIENTS

TESTIMONIALS

What They Say?

SEND US YOUR FEEDBACK

Get a face-to-face appoinment with our qualified specialists

PHONE NUMBER

+ 924 888 0250

EMAIL ADDRESS

hello@spirit.health

OUR LOCATION

Crown Rd. 14b, San Diego, California


© 2021 / Spirit Health / All rights reserved

Malcare WordPress Security